Whittier Trust’s PTC Therapeutics PTCT Stock Holding History

Whittier Trust’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32	Closed	-$1K	–	1750
2022 Q1	$1K	Buy	+32	New	+$1.23K	﹤0.01%	1661

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Whittier Trust's PTCT Position: Q2 2022 in Review

Whittier Trust sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 32 shares — an estimated $1K sold.

Whittier Trust first reported a position in PTCT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 180 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

Whittier Trust reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
Whittier Trust sold 32 PTC Therapeutics shares in Q2 2022, an estimated $1K.
Whittier Trust first reported a position in PTC Therapeutics in Q1 2022 and held it in 1 quarter.
Whittier Trust's PTC Therapeutics position peaked at $1K in Q1 2022.
180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Whittier Trust's 13F filing for Q2 2022, filed 28 Jul 2022.